First-Ever Point-Of-Care COVID-19 Serology Test Granted EUA By FDA
The US agency on 23 September granted emergency use authorization for the Assure COVID-19 IgG/IgM Rapid Test Device to be used in point-of-care settings like doctor’s offices, hospitals, urgent care centers and emergency rooms. The test requires a fingerstick to draw blood.
You may also be interested in...
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.
Cue’s point-of-care molecular test earned an FDA emergency use authorization in June.
The US FDA’s diagnostics chief says the agency isn’t seeing many submissions for rapid antigen tests, but is eager to authorize them.